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Abstract 
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trigger, double trigger 
The aim of the review is to analyse the combination of a gonadotrophin releasing 
hormone (GnRH) agonist with a human chorionic gonadotrophin (hCG) trigger, for 
final oocyte maturation in in vitro fertilisation (IVF) cycles. The concept being a ‘‘dual 
trigger’’combines a single dose of the GnRH agonist with a reduced or standard dosage 
of hCG at the time of triggering. The use of  a GnRH agonist with a reduced dose of 
hCG  in high responders demonstrated luteal phase support with improved pregnancy 
rates, similar to those after conventional hCG and a low risk of ovarian 
hyperstimulation syndrome. The administration of a GnRH agonist and a standard hCG 
in normal responders, demonstrated significantly improved live-birth rates and a higher 
number of embryos of excellent quality, or cryopreserved embryos. The concept of  the 
„double trigger“, represents a combination of a GnRH agonist and a standard hCG, 
when used 40 and 34 hours prior to ovum pick-up, respectively. The use of  the „double 
trigger“ has been successfully offered in treatment of empty follicle syndrome and in 
patients with a history of immature oocytes retrieved or with low/poor oocytes yield. 
Further prospective studies are required to confirm the aforementioned observations 
prior to clinical implementation.  
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Introduction 
During in vitro fertilisation (IVF) treatment a single bolus of 5,000–10,000 IU human 
chorionic gonadotrophin (hCG) has been routinely used for decades as a substitute for 
the endogenous luteinizing hormone (LH) surge, to induce luteinization of the granulosa 
cells, final oocyte maturation and resumption of meiosis  prior to oocyte retrieval due to 
the fact that LH and hCG bind and activate the LH/hCG receptor. However, ovarian 
hyperstimulation syndrome (OHSS) can appear 3–7 days after hCG triggering, or 
during early pregnancy, 12–17 days after hCG administration in patients at risk.  
Therefore the withholding of the ovulation-inducing trigger of hCG with cycle 
cancellation was used to eliminate the syndrome [1].  
Although a single bolus of hCG has long been the gold standard for triggering 
final oocyte maturation and ovulation, it was later demonstrated by introducing 
gonadotrophin releasing hormone (GnRH) antagonist protocols with gonadotrophins, 
that the use of GnRH agonists for final oocyte maturation represents a valuable 
alternative for classical hCG-triggering. Since the GnRH agonist trigger may allow a 
more physiological surge of LH and follicle stimulating hormone (FSH) with the shorter 
duration (approximately 34 hours), it has often been shown to be beneficial in GnRH 
antagonist protocols for preventing OHSS in patients at risk, when compared  with the 
prolonged elevation of hCG trigger (≥6 days) [2]. Recent evidences from an updated 
Cochrane review suggest that final oocyte maturation triggering with the GnRH agonist, 
instead of hCG, in fresh autologous GnRH antagonist IVF cycles, effectively prevents 
mild, moderate or severe OHSS. However, a lower live birth rate and a higher rate of 
early miscarriage compared with the conventional hCG triggered cycles have been 
reported. Therefore, the routine use of a GnRH agonist as the lone trigger for final 
 4 
oocyte maturation in fresh IVF autologous cycles was discouraged. It was considered 
that it could be useful for women who choose to avoid fresh transfers, women who 
donate oocytes to recipients or women who wish to freeze their eggs for later use in the 
context of fertility preservation [3]. However, it should be noted that the authors did not 
recognize that luteal support was the variable responsible for lower pregnancy rates 
because the luteal phase support differed among studies included in the Cochrane 
analysis. Therefore, a meaningful comparison between GnRH agonists and the hCG 
trigger must be confined to outcome measures that are not affected by the luteal support 
regime used. Although the GnRH agonist trigger is effective for preventing OHSS by 
inducing quick and reversible luteolysis, the inferior pregnancy outcomes have been 
attributed to defective luteal phase function and decreased endometrial receptivity. 
Therefore, modifications of the standard luteal phase support are mandatory  to achieve 
acceptable pregnancy rates similar to that of the hCG trigger after fresh embryo transfer. 
Recently, several methods have been accepted to improve the luteal phase in IVF cycles 
triggered with a GnRH agonist including aggressive steroidal luteal support  (American 
approach), or low-dose hCG (1 500 IU) on the day of oocyte retrieval (European 
approach), to allow successful fresh embryo transfer. In addition, with the availability of 
vitrification, segmentation in GnRH agonist-triggered cycles and freezing all 
oocytes/embryos followed by a frozen transfer in an unstimulated cycle, may be the 
optimal optimal strategy for eliminating OHSS [4-9]. 
In recent years, several promising modifications of ovulation triggering using a 
single bolus of GnRH agonist concomitant with a reduced or standard dosage of hCG 
have been investigated, attempting to rescue the luteal phase and to further optimise 
pregnancy outcomes in cycles with GnRH  antagonist protocols (dual trigger) [1,10-
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13,15-17,19-21]. One of the suggested optional methods is the addition of low-dose 
(1000 to 2500 IU) hCG rescue on the day of GnRH agonist triggering in high 
responders at risk of OHSS, which has been shown to be effective in achieving 
acceptable pregnancy rates similar to those obtained after conventional hCG triggering 
with a very low risk of  the syndrome [1,10-12]. Another strategy for final follicular 
maturation, the concomitant administration of both a GnRH agonist and a standard 
bolus of hCG (5000–10,000 IU) in normal responders, demonstrated significantly 
improved implantation, clinical pregnancy and live-birth rates in GnRH-antagonist IVF 
cycles [15],  or a higher number of embryos of excellent quality and cryopreserved 
embryos [16]. Furhermore, using a combination of a GnRH agonist and a standard dose 
of hCG in patients with a previous history of > 25% immature oocytes retrieved,  a 
significantly higher proportion of mature oocytes has been retrieved [17]. Since the 
percentage of mature oocytes can be increased by prolonging the interval > 36 h 
between hCG injection and oocyte retrieval [18], it was reported that prolonging the 
time between ovulation triggering and ovum pickup using a GnRH agonist combined 
with a standard hCG dose (40 and 34 hours), resulted in successful treatment in a 
recurrent case of empty follicle syndrome [19]. The aforementioned indication for the 
effective use of co-administration of a GnRH agonist and a hCG for final oocyte 
maturation, 40 and 34 hours prior to ovum pickup (double trigger), has been  
successfully extended as a valuable new tool in the armamentarium for treating patients 
with low/poor oocytes yield and in cases with a high proportion of immature oocytes 
[20,21]. The purpose of the review is to analyse current ovulation triggering regimens 
using co-administration of a GnRH-agonist with different doses of hCG for final oocyte 
maturation in patients undergoing IVF prior to routine implementation. 
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Dual trigger 
Despite the fact that triggering of ovulation with a GnRH agonist and 1500 IU hCG 35 
h later in GnRH antagonist IVF cycles provides a normal luteal phase and pregnancy 
outcome comparing with a single bolus of 10,000 IU of hCG [22], concomitant 
administration of a GnRH agonist and the low hCG doses have been introduced as a so-
called „dual trigger“. The concept of a dual trigger has been investigated for IVF high 
responders who had significant risk factors for OHSS  to aid in oocyte maturation and 
more sustained support for the corpus luteum. After at least three follicles exceeded 18 
mm in fresh autologous GnRH antagonist-regulated cycles with gonadotrophins of  
IVF, the patients at risk of developing severe OHSS were treated with a combination of 
leuprolide acetate (4 mg) and hCG (1,000 to 2,500 IU) injections based on a patient's 
weight (≤33 IU/kg). Acceptable rates of fertilization (62.8%), implantation (47.5%), 
clinical pregnancy (53.3%), ongoing pregnancy (53.3%), and early pregnancy loss 
(17.2%), along with the absence of OHSS,  have been reported in high responders after 
triggering final oocyte maturation with a combination of leuprolide acetate and low 
doses of hCG. The findings of the study suggested  that concomitant administration of a 
GnRH agonist and hCG for final oocyte maturation appears to be effective and safe in 
terms of the ability to achieve ongoing pregnancies and reduced OHSS risk in patients 
with significant risk factors for the syndrome [10]. Similar results were confirmed by 
the same authors after fresh autologous blastocyst transfers in high responders with 
gonadotrophins and GnRH antagonist cotreatment, compared with the use of a GnRH 
agonist trigger alone with standard or enhanced luteal support, and a GnRH agonist with 
concomitant low-dose hCG. The beneficial effect of  a dual trigger in patients receiving 
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concomitant low-dose hCG (≤33 IU/kg) and leuprolide acetate (4 mg) was evidenced by 
greater ongoing pregnancy (57.7%) (p<.001), or implantation rates (48.8%) (p<.001), 
and reduced pregnancy loss rates (23.4%) (p<.001), with the incidence of clinically 
significant OHSS being 0.5% (p=.723). Similarly, the use of more-aggressive luteal 
support after the GnRH agonist trigger, was also associated with superior reproductive 
outcome (50% vs. 37.8% vs. 20%, respectively) when compared with the GnRH agonist 
alone and standard luteal support (20,6% vs.25.3% vs.58.2%, respectively) (p<.001) 
with no cases of OHSS (p=.723) [11]. Since the lower pregnancy rates after the GnRH 
agonist trigger with peak estradiol (E2) <4,000 pg/mL and intensive luteal support were 
attributed to the lower LH levels on the day of trigger [23], the use of the dual trigger 
with GnRH agonist and low-dose hCG compared the reproductive outcome with GnRH 
agonist trigger alone in high responders with peak E2 <4,000 pg/mL. It appears that the 
dual trigger with low-dose hCG (1,000 IU) and leuprolide acetate (1 mg) combined with 
intensive luteal support is an effective strategy with only one case of mild OHSS and a 
significantly higher live birth rate (52.9% vs. 30.9%) (p=.03), implantation rate (41.9% 
vs. 22.1%) (p<.01) and clinical pregnancy rate (58.8% vs. 36.8%) (p=.03) compared 
with the GnRH agonist trigger group [12].  
Aiming to improve oocyte and embryo quality and the consequent IVF outcome 
in cycles treated with a GnRH antagonist protocol, the concomitant administration of 
both the GnRH agonist and a standard bolus of hCG (5000–10,000 IU) prior to oocyte 
retrieval have been introduced as a new strategy for final follicular maturation in normal 
responders in a limited number of studies [13,15-17]. In the first ever prospective 
randomised study on dual triggering the administration of triptorelin (0.2 mg) at the 
time of hCG administration in GnRH antagonist IVF cycles significantly improved 
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ongoing pregnancy rates compared with the use of the hCG (5000 IU) trigger alone 
(36.1% vs. 22.3%, respectively) (p=.046). It was suggested that the GnRH antagonist 
used in IVF cycles binds to endometrial GnRH receptors, provoking events that 
putatively interfere with implantation. However, the use of a preovulatory GnRH 
agonist may overcome this putative interference by displacing the bound GnRH 
antagonist from the endometrial GnRH receptor, thus enabling proper post-receptor 
actions for improvements in implantation. Another possible explanation for improved 
results in GnRH agonist triggered cycles is the induction of an FSH surge in addition to 
the LH surge which  has been postulated to be instrumental in resumption of some of 
the oocyte's meiotic processes, conferring some advantages to developing embryos [13]. 
Similar observations about the beneficial effects of GnRH agonists resulting in higher 
rates of implantation and ongoing pregnancy  after IVF in GnRH antagonist cycles were 
demonstrated in a later meta-analysis following the administration of a single dose of 
GnRH agonist in the luteal phase. The possible mechanisms responsible for the effects 
of the GnRH agonist luteal action may be a direct beneficial effect on the embryos or 
uterine tissue. Nevertheless, it seems premature to recommend the use of the GnRH 
agonist in the luteal phase until further randomised controlled trials are provided [14]. 
In the light of these preliminary results further investigations regarding the efficacy of 
dual triggering have investigated whether a single dose of GnRH agonist with a 
standard dosage of hCG could improve live-birth rates for normal responders in GnRH 
antagonist IVF cycles. A retrospective cohort study a total of  376 normal responders 
who had undergone IVF using a GnRH antagonist protocol with either a standard dosage 
of recombinant hCG trigger (250 mcg), or the dual trigger (0.2 mg of triptorelin and 250 
mcg of recombinant hCG). The dual trigger group demonstrated a statistically 
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significant increase in the number of oocytes retrieved (12.4 vs.10.1) (p<.01), matured 
oocytes (10.5 vs. 8.1) (p<.01), and the number of embryos cryopreserved (1.9 vs.1.6) 
(p<.01), with the consequent significant increase in implantation (29.6% vs. 18.4%) 
(p<.001), clinical pregnancy (50.7% vs. 40.1%) (p=.047) and live-birth (41.3% vs. 
30.4%) (p=.042)  rates, compared with the hCG trigger group [15]. In a subsequent 
prospective randomised controlled trial of 120 normal responders using recombinant 
FSH with GnRH antagonists, the IVF outcome following either, 5000 IU of hCG trigger 
or a combination of GnRH agonist plus 5000 IU of hCG concomitantly, the role of the 
GnRH agonist induced FSH surge on the number of metaphase II (MII) oocytes and 
hormonal profiles was investigated. There was no difference reported in the number of 
mature oocytes obtained between the groups, however in the group with dual triggering 
a significant increase of morphologically excellent embryos accompanied by a 
significant increase in the number of patients with cryopreserved supernumerary 
embryos was observed. The number of patients who received at least one embryo of 
excellent quality (45 out of 61 patients or 73.8%), and the number of cryopreserved 
embryos (33 out 61 or 54.1%) were significantly higher following the dual trigger 
(p<.001 and p<.04) compared with the group with hCG triggering alone (28 out of 59 
patients or 47.5% vs. 21 out of 59 or 35.6%, respectively). The mean number of MII 
oocytes in the hCG triggered group was 9.2 compared with 10.3 in the hCG-GnRH 
agonist group and there was no statistically significant difference in the number of 
cumulus oocyte complexes. The hormonal curves showed a significantly higher level of 
LH and FSH immediately after triggering in the combination group with no difference 
in the  E2 and progesterone levels in the luteal phase. However, the pregnancy rate in 
the dual triggering group was lower than that obtained in the group triggered by hCG 
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alone, despite the fact that the number of good quality embryos was significantly lower 
in the hCG-only triggered group. Although the reason for this discrepancy is still 
unclear, a possible explanation could be a negative effect on the endometrial receptivity, 
induced by the higher LH levels and the additional FSH surge. Further research with the 
cryopreserved embryos is required to elaborate whether pregnancy rates are indeed 
lower after the combined triggering, despite the improvement of embryo quality, since 
the frozen/thawed cycles are not affected by the potential negative effect of the dual 
triggering on the endometrium [16]. Following the successful use of a dual trigger with 
a GnRH agonist and a standard dose of hCG in a patient with repetitive immature 
oocytes and empty follicle syndrome [24], in a later retrospective cohort study the 
percentage of mature oocytes retrieved in patients with a previous history of >25% 
immature oocytes retrieved has been evaluated  with the use of  the dual trigger. It was 
hypothesised that the endogenous LH and FSH released by the GnRH agonist bolus, in 
addition to the hCG, would result in a larger proportion of mature oocytes in patients 
with a history of poor oocyte maturation after the hCG trigger alone.  All patients in the 
study used the intracytoplasmic sperm injection (ICSI) technique for fertilization, so 
that the oocyte maturation could be assessed. The proportion of mature oocytes 
retrieved was significantly higher in patients using a GnRH antagonist controlled 
ovarian stimulation protocol with recombinant FSH who were triggered with a 
combination of 1 mg leuprolide acetate plus 5,000–10,000 IU  hCG compared with the 
subject's previous cycle  who were triggered only with the same dose of hCG (75.0% vs. 
38.5%, respectively) (p<.01). However, despite the fact that  with a combination of 
GnRH agonist and hCG the percentage of mature oocytes signficantly improved, the 
implantation, clinical and ongoing pregnancy rates for the dual trigger were 
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disappointing (11.8%, 26.1% and 17.4%, respectively) which may be due to an 
underlying oocyte dysfunction in folliculogenesis [17]. 
 
Double trigger 
Since the prolonged luteinization to oocyte retrieval increased the production of 
oocytes of fully expanded cumulus, which may reflect oocyte maturation, it was 
assumed that the subsequent proportion of oocytes proceeding to fertilisation  and 
cleavage also increased. Therefore, in a meta-analysis of 5 randomised controlled trials 
the time interval between hCG priming and oocyte retrieval has been evaluated to 
determine whether a prolonged hCG-to-oocyte retrieval interval is beneficial to IVF 
outcome. The results of the study suggested that the percentage of mature oocytes can 
be increased by prolonging the interval between hCG priming and ovum pick-up (> 
36h), despite the fact  that the fertilisation rate, implantation rate and pregnancy rate do 
not differ significantly between oocyte retrieval <36 h or > 36h after hCG injection and 
oocyte retrieval [18]. By using the advantages and beneficial effects of the prolongation 
of the time between standard hCG triggering prior to ovum pick-upcohort and GnRH 
agonists in a preliminary historical study, the co-administration of the GnRH agonist 
and hCG for final oocyte maturation (40 to 34 h prior to ovum pick-up) has been 
implemented successfully as a new treatment modalitity (double trigger) for treatment 
in a recurrent case of empty follicle syndrome. It was assumed that by prolonging the 
time between ovulation triggering and ovum pick-up with the GnRH agonist trigger and 
the consequent induction of an FSH surge, the „double trigger” could overcome any 
existing impairments in granulosa cell function, oocyte meiotic maturation, or cumulus 
expansion. Although it was impossible to differentiate which of the two strategies 
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yielded the desired outcome, it seems that combining hCG with GnRH agonist and 
prolonging the interval between ovulation triggering and ovum pick-up resulted in the 
aspiration of mature oocytes, pregnancy and delivery [19]. With the aim of evaluating 
whether the double trigger improves the number of oocytes retrieved in patients with a 
low (<50%) number of oocytes retrieved per number of preovulatory follicles, a 
preliminary cohort historical study compared the stimulation characteristics of 8 IVF 
cycles, which included the double trigger to the patients’ previous IVF attempt, 
triggered with hCG-only. The results suggested that patients who received the double 
trigger had a significantly higher number of oocytes retrieved (7.0 vs. 2.3) (p<.02), 
number of 2PN (6.0 vs. 1.7) (p<.002), number of embryos transferred (2.2 vs. 0.8) 
(p<.002), and significantly higher proportions of the number of oocytes retrieved to the 
number of follicles >10 mm (80.3 vs. 18.5) (p<.001), and >14 mm in diameter (118.0 
vs. 23.7) (p<.01) on day of hCG administration, compared with the hCG-only trigger. 
Therefore, the “double trigger” was suggested as a valuable new tool in the 
armamentarium for treating patients with low/poor oocytes yield, despite an apparently 
normal follicular development and E2 levels, and in the presence of optimal hCG levels 
on the day of ovum pick-up. Nevertheless, additional larger prospective studies are 
required to confirm these findings in this and other situations, prior to its routine use 
[20]. Finally, a recent cohort historical study further extended the aforementioned 
indications to the co-administration of a GnRH agonist and hCG for final oocyte 
maturation, 40 and 34 h prior to oocyte retrieval, evaluating whether the double trigger 
might improve the proportions of MII oocytes in patients with low proportion of mature 
oocytes (<66%) per number of oocytes retrieved. The stimulation characteristics of 12 
IVF cycles were compared, which include the cycle with the double trigger to the same 
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patients' previous IVF attempt, triggered with hCG-only. Patients who received the 
double trigger, had a significantly higher number of mature oocytes - MII (6.5 vs. 3.6) 
(p<.008), number of embryos transferred (2.4 vs. 1.1) (p<.03), a significantly higher 
proportion of MII oocytes per number of oocytes retrieved (69.7% vs. 47.1%) (p<.03) 
and a higher number of top quality embryos (3.1 vs. 1) (p<.02), compared with their 
hCG-only trigger. There was six pregnancies achieved the in study group (50%) and 
none in the control group. The beneficial effects of the double trigger in respect to an 
improvement in oocyte maturation and pregnancy rates achieved may be explained by 
the additional prolongation of the time between ovulation triggering and ovum pick-up. 
Since the co-administration of a GnRH-agonist and hCG for final oocyte maturation, 40 
and 34 h prior to ovum pick-up, improves IVF outcome in patients with high proportion 
of immature oocytes, the double trigger is suggested as a valuable tool in the 
armamentarium for treating patients with low proportions of mature oocytes, despite 
normal follicular development and optimal hCG levels on the day of ooocyte retrieval. 
However, further large prospective studies are required to confirm the aforementioned 
recommendation prior to its clinical use [21].  
 
Conclusions 
The concept of  the ‘‘dual trigger’’combines the concomitant use of a single dose of 
GnRH agonist with a reduced or standard dosage of hCG at the time of triggering. The 
administration of GnRH-agonist with a reduced dose of hCG (1000 to 2500 IU) in high 
responders at risk of OHSS has been demonstrated to rescue the luteal phase resulting in 
improved pregnancy rates as compared to a GnRH trigger alone, similar to those 
obtained after conventional hCG trigger and with a very low risk of  the syndrome. The 
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use of both a GnRH agonist and a standard bolus of hCG (5000–10,000 IU) in normal 
responders, demonstrated significantly improved implantation, clinical pregnancy, and 
live-birth rates, or a higher number of embryos of excellent quality and cryopreserved 
embryos and therefore may be offered simultaneously to the standard hCG trigger dose.  
A modification of the „dual trigger“, the so called „double trigger“ which consists of the 
administration of a GnRH agonist and a standard dose of hCG for final oocyte 
maturation, 40 and 34h prior to oocyte retrieval, respectively, differs from the „dual 
trigger“ by the additional prolongation of the time between ovulation triggering and 
ovum pick-up. Since the use of  the „double trigger“ has been successfully extended in 
treatment of empty follicle syndrome and in patients with a previous history of higher 
proportion of immature oocytes retrieved, or low/poor oocytes yield, it may be utilised 
in the improvement of abnormal final follicular maturation. Nevertheless, further 
prospective, randomised controlled studies are required to confirm the beneficial role of 
dual/double triggers prior to clinical implementation. 
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